These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 25780464)

  • 1. Efficacy and safety of sitagliptin compared with sulfonylurea therapy in patients with type 2 diabetes showing inadequately controlled glycosylated hemoglobin with metformin monotherapy: A meta-analysis.
    Hou L; Zhao T; Liu Y; Zhang Y
    Exp Ther Med; 2015 Apr; 9(4):1528-1536. PubMed ID: 25780464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparing the efficacy and safety profile of sitagliptin versus glimepiride in patients of type 2 diabetes mellitus inadequately controlled with metformin alone.
    Srivastava S; Saxena GN; Keshwani P; Gupta R
    J Assoc Physicians India; 2012 Mar; 60():27-30. PubMed ID: 22799111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
    Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
    Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients.
    Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Ragonesi PD; Querci F; Franzetti IG; Gadaleta G; Ciccarelli L; Piccinni MN; D'Angelo A; Cicero AF
    Metabolism; 2010 Jun; 59(6):887-95. PubMed ID: 20015525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of dipeptidyl peptidase-4 inhibitors vs sulfonylurea in metformin-based combination therapy for type 2 diabetes mellitus: Systematic review and meta-analysis.
    Foroutan N; Muratov S; Levine M
    Clin Invest Med; 2016 Apr; 39(2):E48-62. PubMed ID: 27040861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of sitagliptin monotherapy and combination therapy in Japanese type 2 diabetes patients.
    Kubota A; Maeda H; Kanamori A; Matoba K; Jin Y; Minagawa F; Obana M; Iemitsu K; Ito S; Amamiya H; Kaneshiro M; Takai M; Kaneshige H; Hoshino K; Ishikawa M; Minami N; Takuma T; Sasai N; Aoyagi S; Kawata T; Mokubo A; Takeda H; Honda S; Machimura H; Motomiya T; Waseda M; Naka Y; Tanaka Y; Terauchi Y; Matsuba I
    J Diabetes Investig; 2012 Dec; 3(6):503-9. PubMed ID: 24843615
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of treatment with sitagliptin or sulfonylurea in patients with type 2 diabetes mellitus and mild renal impairment: a post hoc analysis of clinical trials.
    Ommen ES; Xu L; O'Neill EA; Goldstein BJ; Kaufman KD; Engel SS
    Diabetes Ther; 2015 Mar; 6(1):29-40. PubMed ID: 25633134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sodium-Glucose Co-Transporter 2 Inhibitors Compared with Sulfonylureas in Patients with Type 2 Diabetes Inadequately Controlled on Metformin: A Meta-Analysis of Randomized Controlled Trials.
    Chen Z; Li G
    Clin Drug Investig; 2019 Jun; 39(6):521-531. PubMed ID: 31041606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Urinary albumin excretion with sitagliptin compared to sulfonylurea as add on to metformin in type 2 diabetes patients with albuminuria: A real-world evidence study.
    Goldshtein I; Karasik A; Melzer-Cohen C; Engel SS; Yu S; Sharon O; Brodovicz K; Gadir N; Katzeff HL; Radican L; Chodick G; Shalev V; Tunceli K
    J Diabetes Complications; 2016; 30(7):1354-9. PubMed ID: 27320183
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sitagliptin: a novel drug for the treatment of type 2 diabetes.
    Choy M; Lam S
    Cardiol Rev; 2007; 15(5):264-71. PubMed ID: 17700385
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
    Rosenstock J; Brazg R; Andryuk PJ; Lu K; Stein P;
    Clin Ther; 2006 Oct; 28(10):1556-68. PubMed ID: 17157112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial.
    Ahrén B; Masmiquel L; Kumar H; Sargin M; Karsbøl JD; Jacobsen SH; Chow F
    Lancet Diabetes Endocrinol; 2017 May; 5(5):341-354. PubMed ID: 28385659
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypoglycemia in patients with type 2 diabetes from India and Malaysia treated with sitagliptin or a sulfonylurea during Ramadan: a randomized, pragmatic study.
    Aravind SR; Ismail SB; Balamurugan R; Gupta JB; Wadhwa T; Loh SM; Suryawanshi S; Davies MJ; Girman CJ; Katzeff HL; Radican L; Engel SS; Wolthers T
    Curr Med Res Opin; 2012 Aug; 28(8):1289-96. PubMed ID: 22738801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative effectiveness of dipeptidylpeptidase-4 inhibitors in type 2 diabetes: a systematic review and mixed treatment comparison.
    Craddy P; Palin HJ; Johnson KI
    Diabetes Ther; 2014 Jun; 5(1):1-41. PubMed ID: 24664619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of Initial Combination Therapy in Treatment-Naïve Type 2 Diabetes Patients: A Systematic Review and Meta-analysis.
    Cai X; Gao X; Yang W; Han X; Ji L
    Diabetes Ther; 2018 Oct; 9(5):1995-2014. PubMed ID: 30155646
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sulfonylurea versus metformin monotherapy in patients with type 2 diabetes: a Cochrane systematic review and meta-analysis of randomized clinical trials and trial sequential analysis.
    Hemmingsen B; Schroll JB; Wetterslev J; Gluud C; Vaag A; Sonne DP; Lundstrøm LH; Almdal T
    CMAJ Open; 2014 Jul; 2(3):E162-75. PubMed ID: 25295236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative Study on Adding Pioglitazone or Sitagliptin to Patients with Type 2 Diabetes Mellitus Insufficiently Controlled With Metformin.
    Jameshorani M; Sayari S; Kiahashemi N; Motamed N
    Open Access Maced J Med Sci; 2017 Dec; 5(7):955-962. PubMed ID: 29362626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metformin-Insulin versus Metformin-Sulfonylurea Combination Therapies in Type 2 Diabetes: A Comparative Study of Glycemic Control and Risk of Cardiovascular Diseases in Addis Ababa, Ethiopia.
    Gebrie D; Manyazewal T; A Ejigu D; Makonnen E
    Diabetes Metab Syndr Obes; 2021; 14():3345-3359. PubMed ID: 34335036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison Between Pioglitazone/Metformin Combination Therapy and Sitagliptin/Metformin Combination Therapy on the Efficacy in Chinese Type 2 Diabetic Adults Insufficiently Controlled with Metformin: Study Protocol of an Open-Label, Multicenter, Non-Inferiority Parallel-Group Randomized Controlled Trial.
    Zhang F; Tang L; Li J; Yan Z; Li J; Tong N
    Diabetes Metab Syndr Obes; 2021; 14():1243-1252. PubMed ID: 33776461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.